Metabolic dysfunction-associated steatotic liver disease (MASLD) is nowadays considered an important risk factor not only for end-stage liver disease but also for cardiovascular diseases. The worldwide prevalence of MALSD in adult population is 38%¹. This high prevalence correlates with the increasing prevalence of obesity. Most patients with MASLD are obese and have dyslipidemia². The risk factors for MASLD are obesity, type 2 diabetes or insulin resistance, arterial hypertension, low high-density lipoprotein (HDL)-cholesterol, high plasma triglycerides, elevated C-reactive protein, elevated alanine aminotranspherase, male sex.
The nomenclature of MALSD has been introduced in 2023 by a Delphi consensus process. The previous term NAFLD (non-alcoholic fatty liver disease) has been criticized, being considered stigmatizing for patients because of the words “alcoholic” and “fatty”. MASLD is defined as the association of a steatotic liver, with more than 5% fat infiltration, usually identified at ultrasonography, with at least one of the following five cardiometabolic risk factors3:
- Body mass index ≥ 25 Kg/m² or waist circumference > 80 cm in women or 94 cm in men;
- Diabetes or antidiabetic treatment or fasting plasma glucose ≥ 5.6 mmol/L or 2 hours post-load serum glucose ≥ 7.8 mmol/L or HbA1c ≥ 39 mmol/L;
- Blood pressure ≥ 130/85 mm Hg or antihypertensive treatment;
- Plasma triglycerides ≥ 1.70 mmol/L or lipid lowering treatment;
- Plasma high-density lipoprotein cholesterol ≤ 1.3 mmol/L in women or 1.0 mmol/L in men or lipid-lowering treatment.
Numerous studies have demonstrated that MASLD associates with several severe conditions. For many years, the focus has been on liver-related complications of MASLD, especially end-stage liver disease. In USA, MASLD became the first cause of liver transplantation⁴. However, the liver-related complications are not the mot common etiology of death in patients with MASLD. These patients usually die from cardiovascular disease, an extrahepatic complication of MALSD³. Other extrahepatic complications are type 2 diabetes mellitus, extra-hepatic cancers, chronic kidney disease. The accumulation of triglycerides in the liver does not increase per se the risk of cardiovascular disease, the available data suggest that the cardiovascular risk is actually linked to cardiometabolic abnormalities. The risk of cardiovascular events increases progressively with the severity of liver disease. The patients with advanced liver fibrosis or cirrhosis have the highest risk of heart failure, stroke, and cardiovascular death, liver fibrosis being a strong predictor for all-cause mortality.
MASLD increases the cardiovascular risk through different mechanisms: insulin resistance, chronic low-grade inflammation, oxidative stress, endothelial dysfunction, liver fibrosis and dyslipidemia. There is a synergy of cardiovascular risk in patients with MASLD and type 2 diabetes: the association of MALSD and type 2 diabetes quadruples the risk of cardiovascular events⁵.
The pillar of MALSD treatment is the lifestyle change. Weight loss through diet and exercise is the most effective strategy to decrease the liver fat and cardiovascular risk. Studies have shown that a weight loss of at least 10% can lead to metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis improvement. An intensive treatment of dyslipidemia and high blood pressure is mandatory. In MALSD patients, statins are recommended, to reduce the cardiovascular risk, being safe end efficient. For the overall metabolic management, anti-hyperglycemic agents are preferred. The current cardiovascular risk scores, such as SCORE-2, have limitations, because they do not include MASLD as a risk factor, leading to an underestimation of the real cardiovascular risk. Therefore, considering MASLD as a risk magnifier may be extremely important for prevention guidelines. Screening for MASLD should be performed in all patients with metabolic risk factors, using simple noninvasive tests, such as FIB-4. The diagnosis of MASLD must be viewed as a window of opportunity for cardiovascular prevention.
“No conflicts of interest”
Address for correspondence:
Camelia C. DIACONU
E-mail: drcameliadiaconu@gmail.com
